ロイコトリエン阻害剤を投与された重症COVID-19肺炎患者はより生存しやすいことがUB研究者により判明( Patients with severe COVID-19 pneumonia treated with leukotriene inhibitors are more likely to survive, UB researchers find)

ad
ad
ad
ad
ad

ビッグデータに基づくレトロスペクティブ研究により、ロイコトリエン阻害剤(LTI)が酸素飽和度の低いCOVID-19患者の死亡を予防することを発見 In a retrospective study based on big data, the researchers found that Leukotriene Inhibitors (LTI)s prevented death in COVID-19 patients with low oxygen saturation

2022-05-24 バッファロー大学(UB)

バッファロー大学の生物医学情報学研究者は、COVID-19肺炎で入院した患者が、ロイコトリエン阻害剤(LTI)とステロイド剤デキサメタゾンを組み合わせて治療した場合、13.5%の生存率が得られることを発見しました。
このレトロスペクティブな研究は、重要な臨床的進歩をもたらすためにビッグデータを使用することの有効性を示しています。

<関連情報>

ロイコトリエン阻害剤とデキサメタゾンの併用は、酸素飽和度の低いCOVID-19患者の死亡予防に有望である Leukotriene Inhibitors with dexamethasone show promise in the prevention of death in COVID-19 patients with low oxygen saturations

Peter L. Elkin[,Skyler Resendez,Sarah Mullin,Bruce R. Troen,Manoj J. Mammen,Shirley Chang,Gillian Franklin,Wilmon McCray and Steven H. Brown
Journal of Clinical and Translational Science  Published:16 May 2022
DOI:https ://doi.org/10.1017/cts.2022.401

Abstract

Introduction:
COVID-19 is a major health threat around the world causing hundreds of millions of infections and millions of deaths. There is a pressing global need for effective therapies. We hypothesized that leukotriene inhibitors (LTI), that have been shown to lower IL6 and IL8 levels, may have a protective effect in patients with COVID-19.

Methods:
In this retrospective controlled cohort study, we compared death rates in COVID-19 patients who were taking a LTI with those who were not taking an LTI. We used the Department of Veterans Affairs (VA) Corporate Data Warehouse (CDW) to create a cohort of COVID-19 positive patients and tracked their use of leukotriene inhibitors between November 1, 2019 and November, 11, 2021.

Results:
Of the 1,677,595 cohort of patients tested for COVID-19, 189,195 patients tested positive for COVID-19. 40,701 were admitted and 38,184 had an oxygen requirement, 1,214 were taking an LTI. The use of Dexamethasone plus a Leukotriene Inhibitor in hospital showed a survival advantage of 13.5% (CI: 0.23% – 26.7%; p<0.01) in patients presenting with a minimal O2Sat of 50% or less. For patients with an O2Sat of <60 and < 50% if they were on LTIs as outpatients, continuing the LTI led to a 14.4% and 22.25 survival advantage if they were continued on the medication as inpatients.

Conclusions:
When combined Dexamethasone and LTIs provided a mortality benefit in COVID 19 patients presenting with an O2 Saturations < 50%.. The LTI cohort had lower markers of inflammation and cytokine storm.

タイトルとURLをコピーしました